% | $
Quotes you view appear here for quick access.

Magal Security Systems Ltd. Message Board

irf944 1 post  |  Last Activity: Jun 30, 2016 8:50 AM Member since: Dec 4, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • GERMANTOWN, Md. and BOSTON, June 30, 2016 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (ZIOP) (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve alignment between both companies as ZIOPHARM broadens its pipeline and advances multiple therapeutic programs into the clinic. The new structure is intended to facilitate increased investment in clinical development by ZIOPHARM, including the execution of pivotal studies, across a number of cellular and gene therapies that it employs.

5.450.00(0.00%)Aug 24 4:00 PMEDT